{
    "clinical_study": {
        "@rank": "137893", 
        "acronym": "FRESH", 
        "arm_group": {
            "arm_group_label": "Propiverine Hydrochloride Administration", 
            "arm_group_type": "Other", 
            "description": "Administration of Propiverine Hydrochloride for 12 weeks"
        }, 
        "brief_summary": {
            "textblock": "This study is to evaluate the efficacy and safety that the occurrence of incontinence is\n      significantly decrease using the propiverine hydrochloride for 200 female patients with\n      mixed (stress and urge) urinary incontinence in one week during a twelve-week treatment\n      period."
        }, 
        "brief_title": "Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Urinary Incontinence", 
        "condition_browse": {
            "mesh_term": [
                "Urinary Incontinence", 
                "Urinary Incontinence, Stress"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Female patients with mixed urinary incontinence (MUI)\n\n          2. Patients having symptoms of urinary incontinence for at least 3 months\n\n          3. Patients having at least one episode of urge urinary incontinence per week and 4\n             episodes of stress urinary incontinence per week in a bladder diary.\n\n          4. 20 years old or older\n\n          5. Patients who meet all the following criteria in ICIQ-SF (1) \"2-3 times or more in one\n             week\" was selected at Q1. (2) \"Small or more\" was selected at Q2. (3) \"leak at the\n             time of cough or sneeze\" or \"leak at the time of exercise\" was selected at Q4.\n\n          6. Less than 100mL of residual urine volume\n\n          7. Written informed consent.\n\n        Exclusion Criteria:\n\n          1. Patients with organ disease such as bladder stones, bladder tumors and urethral\n             stricture in the lower urinary tract\n\n          2. Patients with bacterial infections (i.e. bacterial cystitis) or nonbacterial\n             infections (i.e. interstitial cystitis)\n\n          3. Patients with advanced lower urinary tract obstruction or urinary retention\n\n          4. Patients without urinary sensation\n\n          5. Patients with overflow incontinence\n\n          6. Patients with history or complications of pelvic organ prolapse\n\n          7. Patients with pyloric, duodenal or intestinal obstruction\n\n          8. Patients with gastric or intestinal atony\n\n          9. Patients with angle-closure glaucoma\n\n         10. Patients with myasthenia gravis\n\n         11. Patients with severe heart disease\n\n         12. Patients with severe constipation\n\n         13. Patients with dementia who are not able to complete the questionnaires\n\n         14. Patients with history of allergic reaction to Propiverine Hydrochloride or other\n             similar medicine\n\n         15. Patients with history of surgery that affect urination such as Trans-Obturator\n             Tape\uff08TOT\uff09or Tension-free Vaginal Tape\uff08TVT\uff09\n\n         16. Women who are pregnant, lactating, potentially pregnant or willing to get pregnant\n\n         17. Patients with previous surgery of the abdomen and pelvis or radiation within 6 months\n\n         18. Patients who started pelvic floor muscle exercise within 3 months\n\n         19. Patients who took Propiverine Hydrochloride or other similar medicine within 2 weeks\n             before entry\n\n         20. Judged as being unsuitable for the trial by physician."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01942681", 
            "org_study_id": "TRIGU1309", 
            "secondary_id": "UMIN000011491"
        }, 
        "intervention": {
            "arm_group_label": "Propiverine Hydrochloride Administration", 
            "description": "Administrate Propiverine Hydrochloride for 12 weeks", 
            "intervention_name": "Propiverine Hydrochloride", 
            "intervention_type": "Drug", 
            "other_name": "Bup-4"
        }, 
        "intervention_browse": {
            "mesh_term": "Propiverine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "female", 
            "mixed urinary incontinence"
        ], 
        "lastchanged_date": "March 5, 2014", 
        "location": {
            "contact": {
                "email": "minagawat@shinshu-u.ac.jp", 
                "last_name": "Tomonori Minagawa, M.D., P\uff48.D.", 
                "phone": "81-263-37-2661"
            }, 
            "facility": {
                "address": {
                    "city": "Matsumoto", 
                    "country": "Japan", 
                    "state": "Nagano", 
                    "zip": "390-8621"
                }, 
                "name": "Shinshu University Hospital"
            }, 
            "investigator": {
                "last_name": "Osamu Nishizawa", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Multi-institution Study on Efficacy and Safety of Propiverine Hydrochloride for Female Patients With Urge and Stress Urinary Incontinence", 
        "other_outcome": [
            {
                "description": "Change in maximum urethral closure pressure during a twelve-week treatment period", 
                "measure": "Maximum urethral closure pressure", 
                "safety_issue": "No", 
                "time_frame": "during a twelve-week treatment period"
            }, 
            {
                "description": "Change in functional profile length during a twelve-week treatment period", 
                "measure": "Functional profile length", 
                "safety_issue": "No", 
                "time_frame": "during a twelve-week treatment period"
            }
        ], 
        "overall_contact": {
            "email": "minagawat@shinshu-u.ac.jp", 
            "last_name": "Tomonori Minagawa, M.D., P\uff48.D.", 
            "phone": "81-263-37-2661"
        }, 
        "overall_contact_backup": {
            "email": "FRESH@tri-kobe.org", 
            "last_name": "Koichi Yamashiro", 
            "phone": "81-78-304-6804"
        }, 
        "overall_official": {
            "affiliation": "Shinshu University Hospital", 
            "last_name": "Osamu Nishizawa, M.D., P\uff48.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in occurrence of incontinence during a twelve-week treatment", 
            "measure": "Occurrence of incontinence", 
            "safety_issue": "No", 
            "time_frame": "during a twelve-week treatment period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01942681"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in the number of protective pad used during a twelve-week treatment period", 
                "measure": "The number of protective pad used", 
                "safety_issue": "No", 
                "time_frame": "during a twelve-week treatment period"
            }, 
            {
                "description": "Change in reduction ratio of the occurrence for incontinence during a twelve-week treatment period", 
                "measure": "Reduction ratio of the occurrence for incontinence", 
                "safety_issue": "No", 
                "time_frame": "during a twelve-week treatment period"
            }, 
            {
                "description": "Change in ICIQ-SF scores during a twelve-week treatment period", 
                "measure": "ICIQ-Short Form(SF) scores", 
                "safety_issue": "No", 
                "time_frame": "during a twelve-week treatment period"
            }, 
            {
                "description": "Change in I-QOL scores during a twelve-week treatment period", 
                "measure": "I-QOL scores", 
                "safety_issue": "No", 
                "time_frame": "during a twelve-week treatment period"
            }, 
            {
                "description": "Change in IPSS-QOL scores during a twelve-week treatment period", 
                "measure": "IPSS-QOL scores", 
                "safety_issue": "No", 
                "time_frame": "during a twelve-week treatment period"
            }, 
            {
                "description": "Change in IPSS symptom scores during a twelve-week treatment period", 
                "measure": "IPSS symptom scores", 
                "safety_issue": "No", 
                "time_frame": "during a twelve-week treatment period"
            }, 
            {
                "description": "Change in OABSS symptom scores during a twelve-week treatment period", 
                "measure": "OABSS symptom scores", 
                "safety_issue": "No", 
                "time_frame": "during a twelve-week treatment period"
            }, 
            {
                "description": "Change in blood pressure during a twelve-week treatment period", 
                "measure": "Blood pressure", 
                "safety_issue": "No", 
                "time_frame": "during a twelve-week treatment period"
            }, 
            {
                "description": "Change in pulse rate during a twelve-week treatment period", 
                "measure": "Pulse rate", 
                "safety_issue": "No", 
                "time_frame": "during a twelve-week treatment period"
            }, 
            {
                "description": "The occurrence of adverse events during a twelve-week treatment period", 
                "measure": "Safety assessment", 
                "safety_issue": "Yes", 
                "time_frame": "during a twelve-week treatment period"
            }
        ], 
        "source": "Translational Research Informatics Center, Kobe, Hyogo, Japan", 
        "sponsors": {
            "collaborator": {
                "agency": "Shinshu University Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Translational Research Informatics Center, Kobe, Hyogo, Japan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}